皮肤鳞状细胞癌前哨淋巴结活检的预后价值:基于NCDB的分析
本研究基于美国国家癌症数据库(NCDB)2012至2020年数据,纳入2730例接受完整手术切除(CSE)±前哨淋巴结活检(SLNB)的皮肤鳞状细胞癌(cSCC)患者。结果显示CSE+SLNB组总生存(OS)优于单纯CSE组(校正HR 0.70,95%CI 0.59-0.82,P<0.001),SLNB阳性者OS较差(HR 2.82,95%CI 2.22-3.58,P<0.0001),SLNB阳性后行完成性淋巴结清扫(CLND)未见OS获益。
要点
- cSCC患者接受SLNB与更好的总生存相关,但可能存在选择偏倚。
- SLNB阳性与总生存期恶化显著相关(HR 2.82)。
- SLNB阳性后行CLND未显示总生存获益(HR 0.63,P=0.221)。
核心结论
- 接受SLNB的cSCC患者观察到总生存获益,但CLND未带来生存获益。
- SLNB阳性与更差的总生存相关,未来需研究明确SLNB在cSCC中的角色。
研究设计与样本
- 回顾性队列研究,使用美国国家癌症数据库(NCDB)2012至2020年数据。
- 纳入接受完整手术切除(CSE) alone或CSE+SLNB的cSCC患者,共2730例。
- 比较两组总生存(OS),并对SLNB状态及追加CLND进行亚组分析。
主要发现
- 2730例患者中42.3%接受SLNB,15.4%SLNB阳性。
- 单因素分析:CSE+SLNB vs 单纯CSE的OS HR 0.85(95%CI 0.74-0.98,P=0.0253)。
- SLNB阳性 vs 阴性患者OS HR 2.82(95%CI 2.22-3.58,P<0.0001)。
- 校正模型:CSE+SLNB vs 单纯CSE的OS HR 0.70(95%CI 0.59-0.82,P<0.001)。
- SLNB阳性患者中,CLND vs 无CLND的OS HR 0.63(95%CI 0.30-1.33,P=0.221)。
临床怎么用
- 对于cSCC患者,SLNB可提供预后信息,SLNB阳性提示生存较差。
- SLNB阳性后是否行CLND需个体化决策,本研究未显示CLND的生存获益。
局限性
- 研究为回顾性设计,可能存在选择偏倚。
- 作者指出SLNB的生存获益可能反映研究人群的选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) often presents localized in the skin, but when it metastasizes to regional lymph nodes prognosis declines. Despite this, the role of sentinel lymph node biopsy (SLNB) in detecting metastasis is not well defined. This study uses the National Cancer Database (NCDB) to evaluate the role of SLNB in cSCC. STUDY DESIGN: Patients with cSCC who underwent complete surgical excision (CSE) alone or CSE + SLNB were selected from the NCDB from 2012 to 2020. Overall survival (OS) in these cohorts was compared. Subgroup analyses of SLNB status and addition of completion lymph node dissection (CLND) were performed. Adjusted hazard ratio (HR) and 95% CI were calculated. RESULTS: Of 2,730 patients, 42.3% underwent SLNB, and 15.4% had positive SLNB. Univariate survival analysis showed better OS in CSE + SLNB vs CSE alone (HR 0.85, 95% CI 0.74 to 0.98, p = 0.0253), and worse OS in SLNB-positive vs -negative patients (HR 2.82, 95% CI 2.22 to 3.58, p < 0.0001). In an adjusted survival model, better OS was associated with CSE + SLNB vs CSE alone (HR 0.70, 95% CI 0.59 to 0.82, p < 0.001), worse OS was associated with male sex, comorbid conditions, T2 or higher tumor, and lymphovascular invasion. Subgroup analysis of SLNB-positive patients showed no OS benefit with CLND (HR 0.63, 95% CI 0.30 to 1.33, p = 0.221). CONCLUSIONS: An OS benefit was seen in patients who underwent SLNB, but not CLND. Although this may reflect a selection bias of the study population, given that a positive SLNB was associated with worse OS and new trials show survival benefit with the use of adjuvant therapies, future studies are needed to define the role of SLNB in patients with cSCC.
引用
- Kesmodel SB, Lopez-Aguiar A, Grossman J, et al. Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma. J Am Coll Surg. 2026. PMID: 41071542. doi:10.1097/XCS.0000000000001657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。